AuraSense's uniquely engineered nanoparticles possess unparalleled biocompatibility and versatility as novel assays within live cells. AuraSense particles exhibit high stability, high binding specificity, and unparalleled transfection efficiency into numerous cell and tissue types. Needing no carriers or transfection agents, they provoke minimal immune response and no known toxicity. As a result, they enable unprecedented interrogation of genetic expression in live cells. These constructs are available as SmartFlareTM detection probes from our commercial partner, EMD Millipore.
AuraSense has also developed nanoparticles that mimic the natural function of HDL ("good" cholesterol). These structures bind cholesterol tightly and have demonstrated activity and minimal toxicity in animal models.
AuraSense's technology originates in the labs of Professors Chad A. Mirkin and C. Shad Thaxton at the Northwestern University International Institute for Nanotechnology. The Company's scientific founders and their developments have been the subject of over 80 national and international awards, 550 publications, and 930 patents.
SmartFlare is a trademark of Merck KGaA
NanoFlare Technology Selected as One of Top 10 Innovations of 2013
A Key NanoFlare Technology Patent Issued in the US
Nanoparticle Could Kill Cancerous Lymphoma Cells
New Way to Kill Lymphoma Without Chemotherapy
Shad Thaxton Wins the Presidential Early Career Award
Intracellular Assays in Living Cells